产品详情
简单介绍：
Anti-Membralin抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-Membralin抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-Membralin
Cat. Number:
Anti-Membralin抗体KL-11322R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
The gene encoding human Membralin, C19orf6, localizes to chromosome 19p13.3. It contains 11 exons, which encode at least two splice variants in human cancer. Membralin is a multi-pass membrane protein and exists either as a long or short form. The long form of Membralin comprises all 11 exons, while the short
Anti-Membralin抗体form contains all exons except exon 10. Expression of different Membralin isoforms depends on tissue type. The long form is expressed in ovarian and colorectal carcinomas, whereas the short form is expressed in breast or pancreatic carcinomas. Because Membralin expression in ovarian carcinomas is highest in serous carcinomas as compared to surface epithelium carcinomas, expression of Membralin may be useful as a novel tumor-associated marker in ovarian serous carcinomas.
Also known as:
ASBABP1; C19orf6; MGC4022;
Anti-Membralin抗体R32184_3; aspecific BCL2 ARE-binding protein 1; C19orf6; chromosome 19 open reading frame 6; MBRL; MBRL_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat,
Anti-Membralin抗体Dog, Pig, Cow, Sheep, Zebrafish.
●
Immunogen: KLH conjugated synthetic peptide derived from human Membralin.
●
Predicted Molecular Weight: 68kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-Membralin抗体
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-Membralin抗体
Optimal working dilutions must be determined by the end user.
